Sabinsa Receives Seven Global Patents

<p>Sabinsa Corporation and its sister company Sami Labs received seven new patents and will increase enforcement action worldwide in order to protect its intellectual property.</p>

Sabinsa Corporation and its sister company Sami Labs received seven new patents, brining the company's total patents to 87. The company has also increased enforcement action worldwide in order to protect its intellectual property.

With 100 scientists continuing to research naturally derived herbal remedies to address common health concerns our patent portfolio is growing exponentially, so we have strengthened our legal teams accordingly to protect our IP," said Muhammed Majeed, Ph.D., chairman and founder of the Sami & Sabinsa group of companies.              

The new patents include:

  • Hong Kong patent HK1098450 for the proprietary process technology behind the Ocufors formulation and ophthalmic applications.
  • Canadian patent 2537820 for Ocufors. The patent discusses the proprietary methodology to solubilize diterpenes like forskolin using randomly methylated &#946;-cyclodextrins. The patented solubilization method enhances the application of diterpenes in ophthalmic therapy.
  • New Zealand patent NZ598630 for the proprietary Saberry and Cococin synergisitic formulation and its protective effect on the dermal papilla cells. This was also awarded U.S. patent US8247003.
  • DPR Korea Patent 1011504 for PteroWhite, which focuses on the ability of pterostilbene to modulate melanogenesis and skin hyper pigmentation.
  • U.S. patent US8394852 for the inotilone derivatives (composition of matter). The invention looks at the synthetic routes for derivatives of 5-methyl-3(2H)-furanone compounds, compositions of matter and biological applications.
  • U.S. patent US8383594 for Olepent. The invention titled Peptides modified with triterpenoids and small organic molecules: synthesis and use in cosmeceuticals" is directed to a pentapeptide linked chemically to the plant derived Oleanolic acid and cosmetic compositions.
  • European patent EP1791423 for Boswellin and the therapeutic potential of boswellic acids in combination with selenium amino acids to effectively manage inflammatory conditions of immunological origin like psoriasis.

Sabinsa manufactures, supplies and markets herbal extracts, cosmeceuticals, minerals, dietary supplements and specialty fine chemicals for the nutritional, cosmetic, pharmaceutical and food industries.

Hide comments

Comments

  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Publish